Back

Temporal trends in lipid-lowering therapy utilization among ASCVD patients: a large-scale database analysis

29 August 2025 (09:30 - 09:40)
Organised by: Logo
Congress Presentation Part of: Changing face of lipid-lowering therapy Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Michal Goldberg

Maccabi Health Services, Tel Aviv (Israel)

5 More presentations in this session

Presentation thumbnail
Predictors of lipid-lowering therapy intensification over 1 year of prospective follow-up in Europe: insights from the SANTORINI study
Doctor C. Aguiar (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Real-world prescribing patterns for lipid-lowering therapy in high cardiovascular risk patients in germany: a cross-sectional analysis
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis
Mr V. Ho (Debrecen, HU)
Abstract Slides Video
Presentation thumbnail
Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomised trials
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
Statin adherence in primary care among patients with hypertension with and without other cardiometabolic diseases
Doctor J. Sandslatt (Gothenburg, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Changing face of lipid-lowering therapy
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 09:30 CET
You may be interested in
thumbnail
Congress Session
Changing face of lipid-lowering therapy
thumbnail
Congress Session
Improving pharmacotherapy in primary prevention
thumbnail
Congress Presentation
Lipid management in high cardiovascular risk patients without prior myocardial infarction or stroke - preliminary data from the VESALIUS-REAL global burden study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources